Journal
CELLULAR ONCOLOGY
Volume 36, Issue 1, Pages 9-13Publisher
SPRINGER
DOI: 10.1007/s13402-012-0109-1
Keywords
Galectin-3; Galectin-4; Metastasis; Colorectal cancer
Categories
Funding
- North West Cancer Research Fund [CR777]
Ask authors/readers for more resources
Development of effective ways to detect metastases is highly desirable for improving the therapeutic strategies and survival of cancer patients. Serum levels of galectin-3 and -4, two members of the galactoside-binding galectin family, have recently been reported to be markedly increased up to 31-fold in the bloodstream of colorectal cancer patients and in particular those with metastases. We found that simultaneous determination of serum galectin-3 and -4 levels in a single assay provides a high specificity and sensitivity in distinguishing colorectal cancer patients without metastases from those with liver metastases. This result was partly attributed by a reciprocal relationship of serum galectin-3 and -4 levels in patients with metastases. Higher serum galectin-3/-4 levels at the time of primary tumour removal in patients who did not exhibit clinically detectable metastases were associated with a trend of a poorer patients' survival in the next 10 years. Simultaneous determination of serum galectin-3 and -4 levels can potentially be used alone or in combination with other assessments to detect colorectal cancer metastases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available